Peptide-drug conjugate designated for targeted delivery to HER2-expressing cancer cells
© 2024 European Peptide Society and John Wiley & Sons Ltd..
Targeted therapy of the highest globally incident breast cancer shall resolve the issue of off-target toxicity concurring with augmented killing of specific diseased cells. Thus, the goal of this study was to prepare a peptide-drug conjugate targeting elevated expression of HER2 receptors in breast cancer. Towards this, the rL-A9 peptide was conjugated with the chemotherapeutic drug doxorubicin (DOX) through a N-succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker. The synthesized peptide-drug conjugate, rL-A9-DOX, was characterized by mass spectrometry. Molecular docking studies, based on binding energy data, suggested a stronger interaction of rL-A9-DOX with the HER2 receptor in comparison to the unconjugated peptide, rL-A9. The cytotoxic effect of the rL-A9-DOX conjugate was observed to be higher in HER2-positive SKOV3 cells compared to HER2-negative MDA-MB-231 cells, indicating selective cell killing. Cellular internalization of the rL-A9-DOX conjugate was evident from the flow cytometry analysis, where a noticeable shift in mean fluorescent intensity (MFI) was observed for the conjugate compared to the control group. This data was further validated by confocal microscopy, where the fluorescent signal ascertained nuclear accumulation of rL-A9-DOX. The present studies highlight the promising potential of rL-A9-DOX for targeted delivery of the drug into a defined group of cancer cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of peptide science : an official publication of the European Peptide Society - (2024) vom: 10. Apr., Seite e3602 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sharma, Amit Kumar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cytotoxicity |
|---|
| Anmerkungen: |
Date Revised 11.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1002/psc.3602 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370901037 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370901037 | ||
| 003 | DE-627 | ||
| 005 | 20240411233251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240411s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/psc.3602 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM370901037 | ||
| 035 | |a (NLM)38600778 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sharma, Amit Kumar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Peptide-drug conjugate designated for targeted delivery to HER2-expressing cancer cells |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 European Peptide Society and John Wiley & Sons Ltd. | ||
| 520 | |a Targeted therapy of the highest globally incident breast cancer shall resolve the issue of off-target toxicity concurring with augmented killing of specific diseased cells. Thus, the goal of this study was to prepare a peptide-drug conjugate targeting elevated expression of HER2 receptors in breast cancer. Towards this, the rL-A9 peptide was conjugated with the chemotherapeutic drug doxorubicin (DOX) through a N-succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker. The synthesized peptide-drug conjugate, rL-A9-DOX, was characterized by mass spectrometry. Molecular docking studies, based on binding energy data, suggested a stronger interaction of rL-A9-DOX with the HER2 receptor in comparison to the unconjugated peptide, rL-A9. The cytotoxic effect of the rL-A9-DOX conjugate was observed to be higher in HER2-positive SKOV3 cells compared to HER2-negative MDA-MB-231 cells, indicating selective cell killing. Cellular internalization of the rL-A9-DOX conjugate was evident from the flow cytometry analysis, where a noticeable shift in mean fluorescent intensity (MFI) was observed for the conjugate compared to the control group. This data was further validated by confocal microscopy, where the fluorescent signal ascertained nuclear accumulation of rL-A9-DOX. The present studies highlight the promising potential of rL-A9-DOX for targeted delivery of the drug into a defined group of cancer cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HER2 | |
| 650 | 4 | |a cytotoxicity | |
| 650 | 4 | |a doxorubicin | |
| 650 | 4 | |a peptide‐drug conjugate | |
| 650 | 4 | |a rL‐A9 | |
| 700 | 1 | |a Sharma, Rohit |e verfasserin |4 aut | |
| 700 | 1 | |a Chauhan, Nitish |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Amit |e verfasserin |4 aut | |
| 700 | 1 | |a Satpati, Drishty |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of peptide science : an official publication of the European Peptide Society |d 1996 |g (2024) vom: 10. Apr., Seite e3602 |w (DE-627)NLM091774357 |x 1099-1387 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:10 |g month:04 |g pages:e3602 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/psc.3602 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 10 |c 04 |h e3602 | ||